Company intelligence / Profile preview

Chevalier

Geneva, Switzerlandchevalierglobal.com ↗

Ownership: Private
Development stage: Commercial

Overview

Atopia Therapeutics' lead compound ATP-R13 has demonstrated beneficial effects on airway hyperresponsiveness, airway remodeling, and inflammation in mouse models of allergic asthma. The therapy aims to be first-in-class for disease modification in type 2 atopic diseases. Clinical trials are anticipated but have not yet been reported.

Therapeutic areas: PulmonologyDermatologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Chevalier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chevalier.

Explore the full profile